To sum up the findings, as in other lipid nanoparticle studies featuring the intramuscular injection route, most of the lipids do in fact reside at the injection site (in this case muscle- see below), however, to a lesser yet still significant extent they can migrate to the liver, spleen, adrenal glands, and, yes, even the ovaries. I've plotted the data points so you can have a look for yourself. Figure A shows all significant distribution sites plotted, Figure B shows distribution curves without reference to the injection site.
As I was researching this topic, I came across a very insightful article from 2012. In this study, published in the scientific journal Controlled Release, researchers found that almost every type of nanoparticle tested, for some reason or another, tended to accumulate in the ovaries:
"Several nanocarrier systems are frequently used in modern pharmaceutical therapies. Within this study a potential toxicity risk of all nanoscaled drug delivery systems was found. An accumulation of several structurally different nanocarriers but not of soluble polymers was detected in rodent ovaries after intravenous (i.v.) administration. Studies in different mouse species and Wistar rats were conducted and a high local accumulation of nanoparticles, nanocapsules and nanoemulsions in specific locations of the ovaries was found in all animals.”
Furthermore, the researchers issued a warning that interventions utilizing this nano-technology should not be approved for use on females before results of long-term studies could be analyzed:
"The findings of this study emphasise[sic] the role of early and comprehensive in vivo studies in pharmaceutical research.”
Source: Andreas Schädlich, Stefan Hoffmann, Thomas Mueller, Henrike Caysa, Cornelia Rose, Achim Göpferich, Jun Li, Judith Kuntsche, Karsten Mäder, Accumulation of nanocarriers in the ovary: A neglected toxicity risk?, Journal of Controlled Release, Volume 160, Issue 1, 2012, Pages 105-112, ISSN 0168-3659,
So there you have it. The answer to the question as to whether or not the ovaries can and do actually accumulate high concentrations of mRNA lipid nanoparticles. The next question then would be "what effect does the spike protein mRNA have on the ovaries?" I will once again reiterate my concerns from a previous post:
"according to my research, producing the Covid-19 spike protein as a “self” protein (via mRNA) means it is eventually encoded into the outer cell membrane (as MHC-I molecules). These can alert inspecting T-cells to attack and destroy upon discovery… And it may take some time for this to occur and symptoms to manifest... Also the mRNA can diffuse into the organ parenchyma (unlike COVID-19 itself) thus setting up a potential for organ-specific autoimmune disease."
The implications of this happening on a population-wide scale would be horrific. Hopefully I'm completely wrong about this. But what if I'm not?
So, this leads me to my last question... Why haven't we been told about the risk to the female reproductive system and... is this really a "depopulation" scheme?
My answer may be disappointing... We just don't know. Unfortunately we'll have to wait and see. Time will tell... But, for now, the most important thing you can do is to prayerfully consider whether or not you'd like to be a part of the experiment.
Entering Wedge Media
P.S.If you havent already seen our eye-opening COVID-19 interview with Dr Jim Meehan click here to watch and share!